SCHEMBL6324441

SCHEMBL6324441

COC(=O)CCc1nc(-c2cccn2C)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.45
LMNA P02545 4/20 0.44
ATM Q13315 1/20 0.44
MCL1 Q07820 1/20 0.43
ALDH1A1 P00352 7/20 0.42
CYP3A4 P08684 1/20 0.42
TP53 P04637 3/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 2/20 0.42
GAA P10253 2/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MITF O75030 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326362 0.86 HPGD (0.56) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6323359 0.86 HPGD (0.43) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6328188 0.82 HPGD (0.41) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL4564362 0.78 HPGD (0.68) HPGDLMNAATMALDH1A1TP53
SCHEMBL6533164 0.76 LMNA (0.41) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6333033 0.74 LMNA (0.61) HPGDLMNAATMALDH1A1TP53
SCHEMBL6328296 0.74 HPGD (0.46) HPGDLMNAATMMCL1ALDH1A1
SCHEMBL6326392 0.73 MAPK1 (0.54) HPGDLMNAATMALDH1A1GAA
SCHEMBL6325140 0.72 LMNA (0.58) HPGDLMNAATMALDH1A1TP53
SCHEMBL6323754 0.72 HTT (0.67) HPGDLMNAATMALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
US-20050070602-A1 Method of modulating immune response by administration of immuno-activation agent NATROGEN THERAPEUTICS, INC. 2005-03-31 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 HPGD 539/4885LMNA 448/4885ATM 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.